Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial.
Phase 4
- Conditions
- Neurocognitive Outcome Assesment in Patients With Perioptic Meningiomas
- Registration Number
- NCT03190122
- Lead Sponsor
- Kasr El Aini Hospital
- Brief Summary
Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
- preoptic meningioma, not recurrent, size is operative.
Exclusion Criteria
- other meningiomas than preoptic , recurrent cases, size is not operative, other medical conditions affect the mental condition of the patient.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Neurocognitive Outcome Assessment using MOCA scale 1 year aggregated by our researchers in data base system in our department.
- Secondary Outcome Measures
Name Time Method Neurocognitive Outcome using neuropsychological assessment questionnaire 1 year aggregated by our researchers in data base system in our department.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are implicated in neurocognitive decline after cavernous sinus peeling in NCT03190122?
How does peri-optic meningioma excision with cavernous sinus peeling compare to standard surgical approaches in neurocognitive outcomes?
Are there specific biomarkers predictive of neurocognitive recovery in patients undergoing cavernous sinus peeling for meningiomas?
What are the potential adverse events associated with cavernous sinus peeling in meningioma surgery and their management strategies?
What adjuvant therapies or neuroprotective agents are being explored alongside meningioma excision to improve cognitive outcomes?